Concepedia

F.D. Tattersall

FT

Statistics

Publications

28

Citations

2.4K

H-Index

22

Active since

1986

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (UK) Limited (United Kingdom)

University of Bradford

United States Military Academy

Age UK

F.D. Tattersall is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacology, medicine, and neuropharmacology.

Publications per year

1986–2018

28

Publications

28

An Inverse Agonist Selective for α5 Subunit-Containing GABAA Receptors Enhances Cognition

Gerard R. Dawson, Karen Maubach, Neil Collinson et al. · Journal of Pharmacology and Experimental Therapeutics · 2006 · 242 citations

, , +17

Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets

F.D. Tattersall, Wayne Rycroft, B. Francis et al. · Neuropharmacology · 1996 · 211 citations

, , +4

Structural Optimization Affording 2-(<i>R</i>)-(1-(<i>R</i>)-3,5-Bis(trifluoromethyl)phenylethoxy)-3-(<i>S</i>)-(4-fluoro)phenyl-4- (3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a Potent, Orally Active, Long-Acting Morpholine Acetal Human NK-1 Receptor Antagonist

Jeffrey J. Hale, Sander G. Mills, Malcolm MacCoss et al. · Journal of Medicinal Chemistry · 1998 · 205 citations · Full text

, , +15

5-hydroxytryptamine m-receptor antagonism to prevent cisplatin-induced emesis

B. Costall, A.M. Domeney, R.J. Naylor et al. · Neuropharmacology · 1986 · 188 citations

, , +10

The novel NK1 receptor antagonist MK–0869 (L–754,030) and its water soluble phosphoryl prodrug, L–758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets

F.D. Tattersall, Wayne Rycroft, M. Cumberbatch et al. · Neuropharmacology · 2000 · 137 citations

, , +5

1–5 of 28